Skip to main content
. 2020 May 26;8(1):e000375. doi: 10.1136/jitc-2019-000375

Figure 2.

Figure 2

Neoantigen load and HLA-class I expression in HR-deficient and HR-proficient HGSC. (A) The number of predicted neoantigens derived from missense, insertion/deletion (indel) and non-stop mutations was determined based on MHC class I binding prediction scores (IC50 <500 nM) and their gene expressions (FPKM ≥1) in HR-deficient and HR-proficient tumors (median, 22). (B) Patients were stratified according to their higher or lower than median numbers of predicted neoAgs, designated neoAghi (with ≥22) or neoAglo (with <22). (C) Mean FPKM values for HLA-A, HLA-B, and HLA-C (HLA FPKM) for HR-deficient and HR-proficient tumors (median, 613.4). (D) Patients were stratified according to their higher or lower than median values, designated HLAhi (≥613.4) or HLAlo (<613.4). FPKM, fragments per kilobase of exon per million fragments mapped; HGSC, high-grade serous ovarian carcinoma; HLA, human leukocyte; HR, homologous recombination; NS, not significant.